Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Other Immunotherapy Approaches in Gastric/GEJ Cancers

December 22nd 2017

Emerging Nivolumab Strategies in Gastric/GEJ Cancers

December 22nd 2017

Practical Considerations for Prescribing Immunotherapy

December 22nd 2017

MSI Testing's Impact on Immunotherapy in Gastric Cancers

December 22nd 2017

Immunotherapy in Advanced/Metastatic Gastric/GEJ Cancers

December 22nd 2017

Advanced/Metastatic Gastric Cancer: Beyond Frontline

December 22nd 2017

Treating Unresectable or Metastatic Gastric/GEJ Cancers

December 22nd 2017

Upfront Therapy Approaches in Gastric/GEJ Cancer

December 22nd 2017

Understanding Prognoses of Advanced Gastric/GEJ cancers

December 22nd 2017

The Molecular-Driven Classification of Gastric Cancers

December 22nd 2017

Classification Guidelines for Gastric/GEJ Cancers

December 22nd 2017

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

December 21st 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

FDA Approves Adjuvant Nivolumab for Melanoma

December 21st 2017

The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

Dr. Schadendorf Discusses Sequencing Agents in Melanoma

December 21st 2017

Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

December 21st 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Immunotherapy Resistance Remains a Puzzle

December 15th 2017

Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.

Dr. Landi on the Association Between Genetic Variance and Melanoma Risk

December 14th 2017

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.

Positive Topline Results Announced for Cemiplimab in Advanced CSCC

December 14th 2017

Results from EMPOWER-CSCC 1 showed that cemiplimab (REGN2810) induced an overall response rate of 46.3% in patients with advanced cutaneous squamous cell carcinoma.

Standard Adjuvant Therapy for Melanoma Within Reach

December 12th 2017

Michael B. Atkins, MD, discusses hotly debated adjuvant treatment options for patients with melanoma, and the potential for neoadjuvant therapy.

Combination Therapies Push Melanoma Field Forward

December 12th 2017

Michael A. Postow, MD, discusses the evolution of combination therapies for patients with melanoma.